+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

SITC-Merck Cancer Immunotherapy Clinical Fellowship Award

Society for Immunotherapy of Cancer

The ideal candidate meets the eligibility criteria above and is at a career stage prior to securing a tenure track faculty position, has not yet secured significant R level funding or other awards on par (ex, DOD, ACS), and should demonstrate how this award will aid in advancing to the next stage in their career.

Selection:

The SITC Awards Review Committee oversees the selection process. The process includes a Letter of Intent (LOI) stage. Thereafter, selected applicants will be invited to Full Application stage. Notifications will be communicated via email.

Terms:

Receipt of this award does not preclude the applicant from obtaining grant support from other sources. Support from the 2026-2027 SITC-Merck Cancer Immunotherapy Clinical Fellowship Award is to be acknowledged in presentations and publications resulting from the research sponsored by the award.

The award is nontransferable. The award recipient will carry out the project as proposed in the application, in accordance with the timeline and budget in the application. The award recipient is directly responsible as an employee to the supporting academic institution. The sponsoring institution is responsible for documenting their role in terms of supporting the education and research efforts as well as providing adequate research capacity, including space and equipment, for the award. The sponsoring institution of the selected awardee is also responsible for ensuring that the terms of this award are compatible with grant support from other sources, if applicable.

SITC may discontinue the award if it is documented that the purpose or the terms of the award are not being fulfilled. In this event, the recipient will be notified in writing of this determination, the reason, and the effective date.

The recipient must submit a halfway point (six months) and a final written progress report to SITC, including disposition of funds. Any unused funds will be returned to SITC. The recipient is invited to submit an abstract during the regular abstract submission process for the chance to present the final results of his/her research at a SITC Annual Meeting.

AI Based Application Success Predictor

🧬 1. Strong Focus on Cancer Immunotherapy (Top Predictor)

SITC funding is highly specialized:

Projects must center on immuno-oncology (IO)
Examples:
- Immune checkpoint inhibitors
- CAR-T / cell therapies
- Tumor microenvironment
- Cancer vaccines

👉 Non-immunotherapy oncology proposals have very low success rates

🔬 2. High Scientific Innovation

Successful proposals typically include:

Novel immune mechanisms or targets
Cutting-edge technologies (single-cell, spatial biology, AI in IO)
New therapeutic strategies

👉 Incremental work is less competitive

🔄 3. Translational Relevance (Critical)

SITC strongly prioritizes:

Bench → bedside applicability
Identification of:
- Predictive biomarkers
- Resistance mechanisms
- Combination strategies

👉 Translational impact is often decisive

🧪 4. Strong Mechanistic Rationale

Clear immune-based hypothesis
Supporting preliminary data
Biological plausibility

👉 Weak mechanistic grounding is a common rejection reason

🤝 5. Alignment with Current Immunotherapy Trends

Higher success rates in projects addressing:

Immunotherapy resistance
Combination therapies (IO + chemo/radiation/targeted therapy)
Personalized immunotherapy
Immune-related adverse events

👩‍🔬 6. Investigator Potential & Mentorship

For fellowships:

Strong mentor in immuno-oncology
Clear training plan

For independent awards:

Proven track record in IO research

🏥 7. Access to Samples & Clinical Context

Availability of:
- Tumor samples
- Patient cohorts
Integration with clinical trials or datasets

👉 Translational IO research requires real patient data

📊 8. Feasible Study Design

Clearly defined aims and endpoints
Realistic timelines
Appropriate experimental models

💰 9. Budget Justification

Efficient use of funds
Alignment with project goals

📑 10. Clear Proposal Presentation

Strong articulation of:
- Innovation
- Immunotherapy relevance
- Clinical significance

👉 Clarity is critical in a highly competitive field

📊 Summary: Key Predictors (Ranked)

Highest impact factors:

Immunotherapy focus (strict requirement)
Innovation in IO
Translational relevance

Moderate predictors:
4. Mechanistic rationale
5. Investigator strength
6. Alignment with IO trends

Supporting factors:
7. Feasibility
8. Sample access
9. Budget & clarity

💡 Insider Insight

Compared to broader cancer funders:

Society for Immunotherapy of Cancer is highly niche and competitive

👉 The key success question:
“Does this meaningfully advance cancer immunotherapy?”

Projects combining:
- Mechanism + biomarker + clinical application
  → have the highest success rates

Specialties

Cancer

Immunology

Eligibility Requirements

Applicants must meet the following criteria to be eligible to apply:

 The applicant must hold an MD, PhD or combined MD/PhD degree

 Currently hold a position at academic institution or government cancer center

 If the applicant has completed postdoctoral or residency training, the applicant must be within four years of completing such training

 The applicant may not yet hold a tenure track faculty position

 The applicant may be in a role such as postdoctoral fellow, instructor, resident, or fellow

 Applicants must be SITC members in good standing at time of submission

Domestic and international applicants are eligible to apply

Sponsor Details

Sponsor Institute/Organizations: Society for Immunotherapy of Cancer

Sponsor Type: Corporate/Non-Profit

Address: 555 East Wells Street, Suite 1100 | Milwaukee, WI | 53202-3823

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity